Medical Oncology 1 - AOU Città Della Salute E Della Scienza Di Torino; Candiolo Cancer Institute, FPO - IRCCS Candiolo; Department of Oncology, University of Turin, Turin, Italy.
Medical Oncology, Ospedale Civile Di Ivrea, Ivrea, Turin, Italy.
Expert Opin Pharmacother. 2021 Apr;22(6):677-684. doi: 10.1080/14656566.2021.1876664. Epub 2021 Feb 12.
: Characteristic of some rare pediatric and adult malignancies, addiction to the oncogene family is also observed in a small fraction of common cancers. Inhibition of their protein products, the Trk kinases, proved a successful treatment strategy for these tumors.: The current paper reviews the clinical development of larotrectinib, a selective inhibitor of the Trk kinase family, for the treatment of fusion-positive cancers. The manuscript includes an overview of the efficacy, safety, pharmacokinetics and pharmacodynamics. The authors sum up by providing the reader with their expert opinion on larotrectinib and its potential future use.: Larotrectinib showed tolerability and high efficacy, regardless of the primary site. In 2018, larotrectinib was granted by the Food and Drug Administration a tissue-agnostic approval for the treatment of solid tumors harboring an fusion. The major challenges will be the implementation of the screening for fusions in the general oncologic population, and the incorporation of larotrectinib into the therapeutic algorithms.
某些罕见儿科和成人恶性肿瘤的特征是，癌基因家族也存在于一小部分常见癌症中。抑制其蛋白产物 Trk 激酶已被证明是这些肿瘤的一种成功治疗策略。
本文综述了 Larotrectinib（一种 Trk 激酶家族的选择性抑制剂）治疗融合阳性癌症的临床开发情况。本文稿包括对疗效、安全性、药代动力学和药效学的概述。作者通过提供他们对 Larotrectinib 的专家意见及其潜在的未来用途，为读者做了总结。
Larotrectinib 表现出良好的耐受性和高效性，与原发部位无关。2018 年，Larotrectinib 获得美国食品和药物管理局的批准，可用于治疗携带融合的实体瘤。主要挑战将是在普通肿瘤患者中实施融合筛查，并将 Larotrectinib 纳入治疗方案。
